Nadeera Kesera De SilvaBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4636 (Published 30 August 2016) Cite this as: BMJ 2016;354:i4636
- Alastair McKelvey
Nadeera Kesera De Silva’s sudden untimely death at the age of 34 has denied research into oesophageal cancer a brilliant and gifted mind, and his family and friends a beloved man. Nadeera was midway into his PhD (funded by the National Institute for Health Research, NIHR) into oesophageal adenocarcinoma at the Medical Research Council’s cancer unit in Cambridge. In the 18 months of his research, he’d already presented his work at leading international meetings and published three papers. His most recent research contribution on the therapeutic significance of mutational signatures has been accepted for publication posthumously to Nature Genetics. Nadeera was using whole genome sequencing data from primary tumours to identify new therapeutic pathways. He also developed individualised assays to detect mutations in blood (ctDNA) from patients with preclinical evidence of relapse. He was designing a trial in which his assays …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial